Janus Henderson Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Janus Henderson Group’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,736	Closed	-$758K	–	2624
2023 Q2	$758K	Sell	19,736 -60	-0.3%	-$1.54K	﹤0.01%	1747
2023 Q1	$458K	Buy	19,796 +9,808	+98%	+$234K	﹤0.01%	2072
2022 Q4	$262K	Buy	+9,988	New	+$221K	﹤0.01%	2036
2022 Q3	–	Sell	-10,003	Closed	-$175K	–	2647
2022 Q2	$175K	Buy	+10,003	New	+$157K	﹤0.01%	2348
2021 Q2	–	Sell	-173,551	Closed	-$2.7M	–	1694
2021 Q1	$2.7M	Hold	173,551	–	–	﹤0.01%	1132
2020 Q4	$2.75M	Buy	+173,551	New	+$2.62M	﹤0.01%	1077
2020 Q3	–	Sell	-51,545	Closed	-$594K	–	1378
2020 Q2	$594K	Buy	+51,545	New	+$711K	﹤0.01%	1179

Janus Henderson Group's KDNY Position: Q3 2023 in Review

Janus Henderson Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 19,736 shares — an estimated $758K sold.

Janus Henderson Group first reported a position in KDNY in Q2 2020 and held it in 7 quarters. The position peaked at $2.75M in Q4 2020. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Janus Henderson Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Janus Henderson Group sold 19,736 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $758K.
Janus Henderson Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
Janus Henderson Group's Chinook Therapeutics, Inc. Common Stock position peaked at $2.75M in Q4 2020.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Janus Henderson Group's 13F filing for Q3 2023, filed 14 Nov 2023.